Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated wi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood Adv
मुख्य लेखकों: Jain, Preetesh, Kantarjian, Hagop, Boddu, Prajwal C., Nogueras-González, Graciela M., Verstovsek, Srdan, Garcia-Manero, Guillermo, Borthakur, Gautam, Sasaki, Koji, Kadia, Tapan M., Sam, Princy, Ahaneku, Hycienth, O’Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, Cortes, Jorge E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2019
विषय:
Myeloid Neoplasia
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436011/
https://ncbi.nlm.nih.gov/pubmed/30885996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025874
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन